News & References

NEWS RELEASE

RYTVELA totally prevents fetal organ injury in inflammatory-induced PTB in mice

Rytvela – new treatment paradigm for preterm birth (PTB) and ensued consequences

Montreal, Canada, February 16, 2017RYTVEL Biotech is pleased to announce that the article:
Antenatal suppression of interleukin-1 protects against inflammation-induced fetal injury and improves neonatal and developmental outcomes in mice was published in the Journal of Immunology. See below for information about the article.
Mathieu Nadeau-Vallée, Peck-Yin Chin, Lydia Belarbi, Marie-Ève Brien, Sheetal Pundir, Martin H. Berryer, Alexandra Beaudry-Richard, Ankush Madaan, David J. Sharkey, Alexis Lupien-Meilleur, Xin Hou, Christiane Quiniou, Ines Boufaied, Jean-Sebastien Joyal, William D. Lubell, David M. Olson, Sarah A. Robertson, Sylvie Girard and Sylvain Chemtob.
In a previous article, published in September 2015 in the same journal, the authors have demonstrated that Rytvela reduces utero-placental inflammation and is efficacious to restore normal term for birth, and significantly reduces newborn death yielding normal growth trajectory.
These data came from three different blinded, separate and independent studies of PTB induces either by IL-1, LPS or LTA.
The new publication uses the same design to the previous one but concentrates on neonatal death and outcome, with focus on brain, lungs and gut. The authors show that Rytvela completely protects fetal/newborn organs from the inflammatory in utero insult. It should be highlighted that brain function assessed by visual-evoked potential was totally preserved in animals treated with Rytvela (versus markedly affected controls).
Rytvela is a new efficient first in class treatment of the cause and ensuing serious consequences of preterm birth.
“We are again very encouraged with these new results which focus on fetal outcome, the main problem of PTB,” said Sylvain Chemtob, MD, PhD, co-founder of Rytvel Biotech and researcher at CHU Sainte-Justine. “Preterm birth (PTB) is the primary cause of mortality of newborn and long term health disability mainly respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, retinopathy of prematurity and brain hemorrhage, and there are no effective treatment today that addresses critically important utero-placental inflammation to the placenta and fetus. Rytvela offers not only to prolong gestation by allowing increased maturation of the fetus, but also reduces neonatal mortality and improves fetal/neonatal outcome, most importantly regarding neuro-development. This is a first”.

The article “Antenatal suppression of interleukin-1 protects against inflammation-induced fetal injury and improves neonatal and developmental outcomes in mice” is available at https://rytvel.com/news-publications-and-credentials/, below the news releases.

About RYTVEL Biotech and Rytvela
RYTVEL Biotech will be the first company exploring a new paradigm therapy to develop Rytvela, an effective drug to end preterm birth to the benefit of women and newborns. Rytvela (a linear 7 amino acid peptide) is the first small drug candidate selective to the major pro-inflammatory interleukin-1 receptor. Pre-clinical studies have been corroborated by three independent academic laboratories (U of Montreal, U of Alberta in Canada, and U of Adelaide, Australia). These blinded studies performed separately and independently demonstrate that Rytvela suppresses utero-placental inflammation, significantly reduces/suppresses preterm birth (PTB), newborn death and prevents major organ disruption including of brain, yielding normal growth trajectory. Rytvela was invented by Dr Sylvain Chemtob and his team at the CHU Sainte-Justine Research Center in Montreal, Canada. www.rytvel.com

About the CHU Sainte-Justine Research Center
CHU Sainte-Justine Research Center is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 200 research investigators, including over 90 clinician-scientists, as well as 385 graduate and postgraduate students focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine. The Center is part of CHU Sainte-Justine, which is the largest mother-child center in Canada and second pediatric center in North America. www.research.chusj.org

About PTB (Preterm birth)

PTB is defined as birth occurring before 37 weeks of gestation and before 32 weeks for early pre-term. PTB occurs in ~10 % of births (~ 550,000 in North America). Early PTB in 2 to 3 % of birth. The major cause of PTB is utero-placental inflammation. The consequences are newborn death (more than 1 million per year worldwide), severe life-long health handicaps especially to brain, lungs and cardiovascular system. The current treatments, namely tocolytic agents have no or very little efficacy, and none of them addresses the utero-placental inflammation. The costs related to PTB in the USA were reported in 2017 to be $40 billion/year.

About the Journal of immunology

The Journal of Immunology (The JI) publishes novel, peer-reviewed findings in all areas of experimental immunology, including innate and adaptive immunity, inflammation, host defense, clinical immunology, autoimmunity and more. The JI is published by The American Association of Immunologists (AAI) and has an impact factor of 5.22.

—— 30 ——

Media Contacts:
Daniel Granger, L.LL., MBA, APR, FSCRP, IAS
T. +1 514 840-7990
M. + 1 514 232-1556
daniel.granger@acjcommunication.com
ACJ Communication

Scientific, Financing and BD Contacts:
Jean Paul Castaigne MD, MBA
Co-Founder and CEO
RYTVEL Biotech
jpcastaigne@jpcbiotech.com
+1 514 518-5500

Sylvain Chemtob MD, PhD
Co-founder and CSO
RYTVEL Biotech
sylvain.chemtob@gmail.com
+1 514 585-4604

RYTVELA totally prevents fetal organ injury in inflammatory-induced PTB in mice (PDF)


NEWS RELEASE

Rytvela will be presented at the Grand Challenges 2016 Annual Meeting in October 2016

Rytvela – new treatment for preterm birth

Montreal, Canada, October 17, 2016 – The Rytvela project will be presented at the Grand Challenges 2016 Annual Meeting that will be held in London on October 23 to 26, 2016. Rytvela is a new efficient treatment of the cause and ensuing serious consequences of preterm birth.

Three pre-clinical blinded in-vivo studies performed separately and independently have confirmed that Rytvela reduces utero-placental inflammation, significantly reduces or suppresses preterm birth (PTB), newborn death and prevents major organ disruption including of brain, yielding normal growth trajectory.

“We are excited to be invited to present in such a prestigious global forum”, said Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS, co-inventor of Rytvela. “Preterm birth (PTB) is the first cause of mortality and morbidity of newborn (more than one million deaths per year Worldwide) and there are no real effective treatment and none of the one utilized today addresses utero-placental inflammation, the major cause of PTB and of insult to the fetus”.

The Rytvela project presentation will cover the following elements:

  • Rytvela is a selective antagonist of the IL-1 receptor with strong anti-inflammatory properties
  • Data from independent studies have shown that Rytvela:
    • Suppresses utero-placental inflammation o Normalizes duration of gestation (to term) in 90% of cases o Significantly reduces the risk of death at birth
    • Normalizes organ histology (brain, lung and ileum / colon)
    • Ensures a normal growth trajectory
    • Normalizes brain function
    • Is active as a preventive and curative treatment

The Global Grand Challenges is an innovation initiative created in 2003 by the Bill and Melinda Gates Foundation.

About Rytvela

RYTVELA explores a new paradigm therapy to develop an effective drug to end preterm birth to the benefit of women and newborns. Rytvela (a linear 7 amino acid peptide) is the first small drug candidate selective to the major pro-inflammatory interleukin-1 receptor. Pre-clinical studies have been corroborated by three independent academic laboratories (U of Montreal, U of Alberta in Canada, and U of Adelaide, Australia). These blinded studies performed separately and independently demonstrate that Rytvela reduces utero-placental inflammation, significantly reduces/suppresses preterm birth (PTB), newborn death and prevents major organ disruption including of brain, yielding normal growth trajectory. Rytvela was invented by Dr Sylvain Chemtob and his team at the CHU Sainte-Justine Research Center in Montreal, Canada. For more information visit: www.rytvel.com

About the CHU Sainte-Justine Research Center

CHU Sainte-Justine Research Center is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 200 research investigators, including over 90 clinician-scientists, as well as 385 graduate and postgraduate students focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine. The Center is part of CHU Sainte-Justine, which is the largest mother-child center in Canada and second pediatric center in North America.

About PTB (Preterm birth)

PTB is defined as birth occurring before 37 weeks of gestation (World Health Organization 2012).
It occurs in ~10 % of births (~ 550,000 in North America).
The major cause is utero-placental inflammation (~70%) presumed secondary to infection (clinical and sub clinical) other are dominated by idiopathic and multiple fetuses.
The consequences are newborn death (more than 1 million per year worldwide), severe life-long health consequences specially brain, lung and ileus/colon.
The current treatments, the tocolytic agents have no or very little efficacy and none of them addresses the utero-placental inflammation.
The costs in the USA were reported by the US Institute of Medicine in 2007 to be $26 billion/year. Normal delivery cost $ 4,500, preterm birth $ 50,000, and after the neonatal period life time medical care reach $500,000 per premature handicapped child PTB.

About Global Grand Challenges Summit

The Grand Challenges in Global Health (GCGH) is a research initiative launched by the Bill & Melinda Gates Foundation [1] in search of solutions to health problems in the developing world. Fifteen challenges are categorized in groups among seven stated goals plus an eighth group for family health. The goals are Improve Vaccines, Create New Vaccines, Control Insect Vectors, Improve Nutrition, Limit Drug Resistance, Cure Infection and Measure Health Status. In that last goal, one of the challenges is preventive preterm birth. So far close to $500 million has being committed to the GCGH and many countries are now participating in that initiative.

—— 30 ——

Media Contacts:

Daniel Granger, L.LL., MBA, APR, FSCRP, IAS
T. +1 514 840-7990
M. + 1 514 232-1556
daniel.granger@acjcommunication.com

Charlotte Blanche
T. + 1 514 840-1235 ext 7772
M. + 1 514 914-0593
c.blanche@acjcommunication.com

Scientific, Financing and BD Contacts:

Jean Paul Castaigne MD, MBA
CEO RYTVEL Biotech
jpcastaigne@jpcbiotech.com
+1 514-518-5500

Sylvain Chemtob MD, PhD
CSO RYTVEL Biotech
sylvain.chemtob@gmail.com
+1 514-585-4604

Rytvela will be presented at the Grand Challenges 2016 Annual Meeting in October 2016 (PDF)


NEWS RELEASE

RYTVEL Biotech is invited to the Hello Tomorrow Challenge Global Summit

Rytvela – new treatment for preterm birth

Montreal, Canada, September 27, 2016 – RYTVEL Biotech is pleased to announce that Hello Tomorrow Challenge has identified the company as one of the most promising Start up around the world. RYTVEL is invited to present its Rytvela project at the Hello Tomorrow Challenge Global Summit that will be held in Paris on October 12 to 14, 2016. Rytvela is a new efficient first in class treatment of the cause and ensuing serious consequences of preterm birth.

Three pre-clinical blinded in-vivo studies performed separately and independently have confirmed that Rytvela reduces utero-placental inflammation, significantly reduces or suppresses preterm birth (PTB), newborn death and prevents major organ disruption including of brain, yielding normal growth trajectory.

“We are excited to be invited to attend such a prestigious global Summit,” said Jean-Paul Castaigne, MD, MBA, founder and CEO of Rytvel Biotech. “Preterm birth (PTB) is the first cause of mortality and morbidity of newborn (more than one million deaths per year Worldwide) and there are no really effective treatment and none of the one utilized today addresses the utero-placental inflammation, the real cause of PTB and of the insult to the fetus”.

  • Rytvela is a selective antagonist of the IL-1 receptor with strong anti-inflammatory property
  • The data of the independent studies have shown that Rytvela:
    • Suppresses utero-placental inflammation
    • Normalizes the term of birth in 90% of the cases
    • Significantly reduces the risks of death at birth
    • Normalizes the organ structure and function (brain, lung and ileum / colon)
    • Is active as a preventive and curative treatment

About RYTVEL Biotech and Rytvela

RYTVEL Biotech will be the first company exploring a new paradigm therapy to develop Rytvela, an effective drug to end preterm birth to the benefit of women and newborns. Rytvela (a linear 7 amino acid peptide) is the first small drug candidate selective to the major pro-inflammatory interleukin-1 receptor. Pre-clinical studies have been corroborated by three independent academic laboratories (U of Montreal, U of Alberta in Canada, and U of Adelaide, Australia). These blinded studies performed separately and independently demonstrate that Rytvela suppresses utero-placental inflammation, significantly reduces/suppresses preterm birth (PTB), newborn death and prevents major organ disruption including of brain, yielding normal growth trajectory. Rytvela was invented by Dr Sylvain Chemtob and his team at the CHU Sainte-Justine Research Center in Montreal, Canada.
https://rytvel.com/

About the CHU Sainte-Justine Research Center

CHU Sainte-Justine Research Center is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 200 research investigators, including over 90 clinician-scientists, as well as 385 graduate and postgraduate students focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine. The Center is part of CHU Sainte-Justine, which is the largest mother-child center in Canada and second pediatric center in North America.

About PTB (Preterm birth)

PTB is defined as birth occurring before 37 weeks of gestation (World Health Organization 2012).
It occurs in ~10 % of births (~ 550,000 in North America).
The major cause is utero-placental inflammation (~70%) presumed secondary to infection (clinical and sub clinical) other are dominated by idiopathic and multiple fetuses.
The consequences are newborn death (more than 1 million per year worldwide), severe life-long health handicaps specially brain, lung and ileus/colon.
The current treatments, the tocolytic agents have no or very little efficacy and none of them addresses the utero-placental inflammation.
The costs in the USA were reported by the US Institute of Medicine in 2007 to be $26 billion/year.
Normal delivery cost $ 4,500, preterm birth $ 50,000, and after the neonatal period life time medical care reach $500,000 per premature handicapped child PTB.

About Hello Tomorrow Challenge and the 2016 Global Summit

Hello Tomorrow is a non-profit organization that aims to bridge the gap between science entrepreneurs, investors, and corporations in all major scientific and technological fields. (Aeronautics, Air Quality, Beauty and Wellbeing, Data & AI, Energy, Food & Agriculture, Healthcare, Industry 4.0, Transportation & Mobility, Water & Waste). Today, it is a global, interdisciplinary community of 15,000 innovators, with a presence across 45 countries. The Hello Tomorrow Challenge, a global startup competition, has attracted nearly 5,000 startups across 112 countries since its inception in 2014. To date, €65 million has been raised by Hello Tomorrow’s finalists. The Hello Tomorrow Global Summit is an intimate, invite-only forum that will gather 2,000 science visionaries and entrepreneurs from around the world at the CENTQUATRE in Paris, France on October 12–14, 2016.

Media Contacts:

Daniel Granger, L.LL., MBA, APR, FSCRP, IAS
T. +1 514 840-7990
M. + 1 514 232-1556
daniel.granger@acjcommunication.com

Charlotte Blanche
T. + 1 514 840-1235 ext 7772
M. + 1 514 914-0593
c.blanche@acjcommunication.com

Scientific, Financing and BD Contacts:

Jean Paul Castaigne MD, MBA
CEO RYTVEL Biotech
jpcastaigne@jpcbiotech.com
+1 514-518-5500

Sylvain Chemtob MD, PhD
CSO RYTVEL Biotech
sylvain.chemtob@gmail.com
+1 514-585-4604

RYTVEL Biotech is invited to the Hello Tomorrow Challenge Global Summit (in PDF)


The Journal of Immunology

Antenatal Suppression of IL-1 Protects against Inflammation-Induced Fetal Injury and Improves Neonatal and Developmental Outcomes in Mice

1 February 2017

Mathieu Nadeau-Vallée, Peck-Yin Chin, Lydia Belarbi, Marie-Ève Brien, Sheetal Pundir, Martin H. Berryer, Alexandra Beaudry-Richard, Ankush Madaan, David J. Sharkey, Alexis Lupien-Meilleur, Xin Hou, Christiane Quiniou, Alexandre Beaulac, Ines Boufaied, Amarilys Boudreault, Adriana Carbonaro, Ngoc-Duc Doan, Jean-Sebastien Joyal, William D. Lubell, David M. Olson, Sarah A. Robertson, Sylvie Girard and Sylvain Chemtob

– Continue Reading


The Journal of Immunology

Novel Noncompetitive IL-1 Receptor−Biased Ligand Prevents Infection- and Inflammation-Induced Preterm Birth

September 25 2015

Mathieu Nadeau-Vallée, Christiane Quiniou, Julia Palacios, Xin Hou, Atefeh Erfani, Ankush Madaan, Mélanie Sanchez, Kelycia Leimert, Amarilys Boudreault, François Duhamel, José Carlos Rivera, Tang Zhu, Baraa Noueihed, Sarah A. Robertson, Xin Ni, David M. Olson, William Lubell, Sylvie Girard and Sylvain Chemtob

– Continue Reading


Elsevier

A critical role of interleukin-1 in preterm labor

30 November 2015

Mathieu Nadeau-Vallée, Dima Obari, Christiane Quiniou, William D. Lubellc, David M. Olson, Sylvie Girard, Sylvain Chemtob

– Continue Reading


The Journal of Immunology

Development of a Novel Noncompetitive Antagonist of IL-1 Receptor

January 23, 2010

Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, Beauchamp M, Leduc M, Rihakova L, Joyal JS, Nadeau S, Heveker N, Lubell W, Sennlaub F, Gobeil F Jr, Miller G, Pshezhetsky AV, Chemtob S.
Characterization of a novel noncompetitive antagonist of IL-1 receptor. J Immunol 180:6977-6987, 2008.

– Continue Reading


Journal of the American Heart Association

Arteriosclerosis, Thrombosis, and Vascular Biology

Microglia and Interleukin-1β in Ischemic Retinopathy Elicit Microvascular Degeneration Through Neuronal Semaphorin-3A

June 13 2013
Rivera JC, Sitaras N, Hamel D, Madaan A, Zhou T, Noueihed B, Blais M, Quiniou C, Joyal J-S, Lubell W, Chemtob S.
Microglia and IL-1 in ischemic retinopathy elicit microvascular degeneration through neuronal Semaphorin 3A. Arterioscl Thromb Vasc Biol 33:1881-91, 2013.

– Continue Reading


The Lancet

Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial

February 23 2016

Jane Elizabeth Norman, Neil Marlow, Claudia-Martina Messow, Andrew Shennan, Phillip R Bennett, Steven Thornton, Stephen C Robson, Alex McConnachie, Stavros Petrou, Neil J Sebire, Tina Lavender, Sonia Whyte, John Norrie, for the OPPTIMUM study group

– Continue Reading


The Lancet

Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial

March 1, 2016

Elvira O G van Vliet, Tobias A J Nijman, Ewoud Schuit, Karst Y Heida, Brent C Opmeer, Marjolein Kok, Wilfried Gyselaers, Martina M Porath, Mallory Woiski, Caroline J Bax, Kitty W M Bloemenkamp, Hubertina CJ Scheepers, Yves Jaquemyn, Erik van Beek, Johannes J Duvekot, Maureen T M Franssen, Dimitri N Papatsonis, Joke H Kok, Joris A M van der Post, Arie Franx, Ben Willem J Mol, Martijn A Oudijk,

– Continue Reading